AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Niladri Roy Chowdhury

Niladri Roy Chowdhury

Novartis Institutes for BioMedical Research - Bhubaneswar / United States
Engineering & Technology / Computer Science
AD Scientific Index ID: 4542766
-
person_outline Niladri Roy Chowdhury's MOST POPULAR ARTICLES
1-) Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525)±anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies Journal for immunotherapy of cancer 10 (2), e003776, 2022
2-) Phase I/II study of LAG525±spartalizumab (PDR001) in patients (pts) with advanced malignancies. Journal of Clinical Oncology 36 (15_suppl), 3012-3012, 2018
3-) Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071 Molecular cancer therapeutics 19 (4), 1031-1039, 2020
4-) Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors Journal for immunotherapy of cancer 9 (11), e003388, 2021
5-) A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies Oncoimmunology 13 (1), 2290787, 2024